Efficacy of oral semaglutide according to diabetes duration: An exploratory subgroup analysis of the PIONEER trial programme

Aims An exploratory analysis of data from the global phase 3a PIONEER programme (PIONEER 1–5 and 7–8 trials) evaluated the efficacy of once-daily oral semaglutide 3, 7, 14 mg versus comparators by diabetes duration at baseline. Methods: Data were included from all PIONEER 1–5, 7 and 8 participants (n = 5657). Patients were grouped by diabetes duration (< 5, 5– < 10 and ≥ 10 years) and by trial. In PIONEER, patients were randomised to oral...